Oracle Alpha’s Ionis Pharmaceuticals IONS Stock Holding History

Oracle Alpha’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-5,019	Closed	-$254K	–	224
2023 Q4	$254K	Buy	+5,019	New	+$240K	0.33%	135

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Oracle Alpha's IONS Position: Q1 2024 in Review

Oracle Alpha sold out of Ionis Pharmaceuticals (IONS) in Q1 2024, closing a stake of 5,019 shares — an estimated $254K sold.

Oracle Alpha first reported a position in IONS in Q4 2023 and held it in 1 quarter. The position peaked at $254K in Q4 2023. 362 funds tracked by Wall St. Rank hold IONS as of Q1 2024.

Oracle Alpha reported no remaining Ionis Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Oracle Alpha sold 5,019 Ionis Pharmaceuticals shares in Q1 2024, an estimated $254K.
Oracle Alpha first reported a position in Ionis Pharmaceuticals in Q4 2023 and held it in 1 quarter.
Oracle Alpha's Ionis Pharmaceuticals position peaked at $254K in Q4 2023.
362 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2024.

Based on Oracle Alpha's 13F filing for Q1 2024, filed 15 May 2024.